Subsequent Events |
9 Months Ended |
|---|---|
Sep. 30, 2025 | |
| Subsequent Events [Abstract] | |
| Subsequent Events |
13. Subsequent Events
Subsequent to September 30, 2025, pursuant to a sales agreement dated November 13, 2024 with Guggenheim Securities, LLC, Unicycive Therapeutics, Inc. (the “Company”) sold 641,033 shares of common stock at an average price of $4.78 per share, resulting in net proceeds to the Company of approximately $3.0 million. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|